Nur77 agonist-1

Nur77 agonist-1 (Compound 8f) is an orally active Nur77 agonist. Nur77 agonist-1 induces ferroptosis by upregulating Nur77 protein expression, increasing reactive oxygen species (ROS) and lipid peroxidation levels, and decreasing GPX4 protein expression. Nur77 agonist-1 has binding affinity to the ligand binding domain (LBD) of Nur77 (KD: 13.80 μM) . Nur77 agonist-1 exhibits significant antiproliferative activity against a variety of breast cancer cells (IC50: 2.15-3.26 μM) and has low toxicity to normal cells. Nur77 agonist-1 can be used in breast cancer research[1].

Product Specifications

CAS Number

[2899254-71-6]

UNSPSC

12352005

Target

Ferroptosis; Glutathione Peroxidase; Nuclear Hormone Receptor 4A/NR4A; Reactive Oxygen Species (ROS)

Related Pathways

Apoptosis; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C(NC1=CC=C(C(N/N=C/C2=CC=CC(Cl)=C2)=O)C=C1)NC3=CC4=CC=CN=C4C=C3

Molecular Formula

C24H18ClN5O2

Molecular Weight

443.89

References & Citations

[1]Gao YF, et al. Design, synthesis, and biological evaluation of quinolinyl-ureido-phenyl-hydrazide derivatives and quinolinyl-hydrazide derivatives as anticancer agents targeting Nur77-mediated ferroptosis. Eur J Med Chem. 2025 Jul 5;291:117559. 40215561.